S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
66,000% upside on tiny biotech? (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
66,000% upside on tiny biotech? (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
66,000% upside on tiny biotech? (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Critical asset just had biggest fall on record (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
66,000% upside on tiny biotech? (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
66,000% upside on tiny biotech? (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
NASDAQ:ETNB

89bio (ETNB) Stock Price, News & Analysis

$11.18
+0.59 (+5.57%)
(As of 02/23/2024 ET)
Today's Range
$10.60
$11.42
50-Day Range
$8.13
$11.99
52-Week Range
$6.57
$22.93
Volume
1.21 million shs
Average Volume
1.32 million shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.56

89bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
182.3% Upside
$31.56 Price Target
Short Interest
Bearish
10.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.14mentions of 89bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.07) to ($2.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.99 out of 5 stars

Medical Sector

796th out of 936 stocks

Pharmaceutical Preparations Industry

365th out of 427 stocks


ETNB stock logo

About 89bio Stock (NASDAQ:ETNB)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

ETNB Stock Price History

ETNB Stock News Headlines

89bio Inc
ETNB Mar 2024 15.000 call
Public Service Announcement: New National Emergency Incoming
Americans urged to share this new documentary with their friends and family before this looming event triggers a new national crisis… 
ETNB Mar 2024 7.500 put
Is this AI's biggest breakthrough to date?
In the past year, AI has amazed us all with its achievements. It can predict weather, recommend winning stocks, create original art, write computer code, detect skin cancer – and, shockingly, it can do all these things better than most humans. But when you see its latest leap (revealed in on-location footage), you may want to pinch yourself! 
Buy Rating Affirmed for 89bio Amid Promising NASH Drug Developments
Buy Rating Affirmed for 89bio Amid Promising NASH Drug Developments
See More Headlines
Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
2/25/2024
Next Earnings (Estimated)
3/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ETNB
Fax
N/A
Employees
45
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.56
High Stock Price Target
$50.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+182.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-102,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.00 per share

Miscellaneous

Free Float
89,105,000
Market Cap
$1.04 billion
Optionable
Optionable
Beta
1.00
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Rohan  PalekarMr. Rohan Palekar (Age 58)
    CEO & Director
    Comp: $990.52k
  • Mr. Quoc Le-Nguyen (Age 56)
    Chief Technical Operations Officer & Head of Quality
    Comp: $654.44k
  • Dr. Harry Mansbach M.D. (Age 59)
    Chief Medical Officer
    Comp: $691.87k
  • Mr. Ryan Stephen Martins (Age 46)
    Chief Financial Officer
  • Mr. Shiva K. Natarajan (Age 58)
    Senior Vice President of Finance & Principal Accounting Officer
  • Ms. Annie J. Chang M.B.A.
    VP of Investor Relations & Corporate Communications
  • Ms. Amanda Kurihara
    Vice President of People & Culture
  • Ms. Yun Bai
    VP and Head of Chemistry, Manufacturing & Controls ( CMC )
  • Ms. Melissa Abel
    Senior Vice President of Commercial Strategy
  • Mr. Paul Shin
    Senior Vice President of R&D Operations














ETNB Stock Analysis - Frequently Asked Questions

Should I buy or sell 89bio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ETNB shares.
View ETNB analyst ratings
or view top-rated stocks.

What is 89bio's stock price target for 2024?

6 Wall Street analysts have issued 12-month price targets for 89bio's stock. Their ETNB share price targets range from $15.00 to $50.00. On average, they anticipate the company's share price to reach $31.56 in the next twelve months. This suggests a possible upside of 182.3% from the stock's current price.
View analysts price targets for ETNB
or view top-rated stocks among Wall Street analysts.

How have ETNB shares performed in 2024?

89bio's stock was trading at $11.17 at the start of the year. Since then, ETNB stock has increased by 0.1% and is now trading at $11.18.
View the best growth stocks for 2024 here
.

When is 89bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024.
View our ETNB earnings forecast
.

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) released its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.08. The firm earned $1 million during the quarter, compared to the consensus estimate of $0.38 million. 89bio's revenue for the quarter was up .0% on a year-over-year basis.

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

When did 89bio IPO?

(ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Who are 89bio's major shareholders?

89bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include RTW Investments LP (5.99%), Vanguard Group Inc. (4.62%), BVF Inc. IL (4.34%), Frazier Life Sciences Management L.P. (2.15%), Federated Hermes Inc. (2.11%) and Westfield Capital Management Co. LP (1.89%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends
.

How do I buy shares of 89bio?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ETNB) was last updated on 2/25/2024 by MarketBeat.com Staff